Follow us...


Search News Archives

News Channels


Coronavirus (COVID-19)


View Channel

New Laboratory Products


View Channel

Lab News


View Channel

Research & Case Studies


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel



View Channel

Events | Webinars


View Channel

Conferences | Events

Molecular Methods Rapidly Gain Ground in Infectious Disease Diagnostics

publication date: Jan 20, 2015
author/source: Frost & Sullivan

Convergence of immunodiagnostic and molecular tests will help meet demand in developed countries, says Frost & Sullivan

/Frost and SullivanUnique disease outbreaks across the globe are escalating the demand for screening and spurring the infectious disease diagnostic market. 

The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular diagnostics is growing the fastest among the infectious disease market segments, clocking a compound annual growth of 15.30 percent. Although these tests remain expensive, their efficiency and accuracy strengthen their use case. 

New analysis from Frost & Sullivan’s Analysis of the Global Infectious Disease Diagnostics Market finds the market earned revenue of $7.91 billion in 2013 and estimates this to reach $12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests will be the major revenue generators. 

“Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” saidFrost & Sullivan Life Sciences Industry Analyst Aish Vivekanandan. “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.” 

While decentralized and rapid tests are a growing trend in the developed world, high costs affect the market in developing countries. Stringent regulations further complicate product development and marketing. 

Another challenge is the low awareness of products among consumers across regions. Diagnostic companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field. 

“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity and accuracy,” noted Vivekanandan. “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global infectious disease diagnostics market.” 

Analysis of the Global Infectious Disease Diagnostics Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related studies include: Global In Vitro Diagnostics Market, US Hematology Diagnostics Market, Global Next-generation Sequencing Market, and Western European Companion Diagnostics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. 

more about frost & sullivan




Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd



Media Partners